. 2020 Nov 17;184(2):267–276. doi: 10.1530/EJE-20-0325
This work is licensed under a Table 3.
Treatment-naïve/prepubertal (NPP) patient characteristics at baseline in responders and poor-responders without LS (enrolled population). Responders were defined as patients with change in height SDS in year 1 of ≥0.3; poor-responders were defined as patients with change in height SDS in year 1 of <0.3.
| Characteristics | NPP-non LS poor responder (n = 38) | NPP-non-LS responder (n = 50) | P valuea | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| nb | n (%) | Mean (s.d.) | 95% CI | Median (Q1; Q3) | n b | n (%) | Mean (s.d.) | 95% CI | Median (Q1; Q3) | ||
| Females | 38 | 11 (28.9) | 17.0; 44.8 | 50 | 20 (40.0) | 27.6; 53.8 | 0.282c | ||||
| Age at first injection, years | 38 | 10.28 (3.53) | 9.12; 11.44 | 10.86 (7.82; 13.47) | 50 | 7.00 (3.11) | 6.12; 7.88 | 6.28 (4.19; 9.33) | <0.001f | ||
| Height, SDS | 38 | −3.44 (0.90) | −3.74; −3.15 | −3.28 (−3.74; −3.03) | 50 | −3.49 (1.15) | −3.81; −3.16 | −3.27 (−3.99; −2.84) | 0.930f | ||
| Height velocity, cm/year | 18 | 4.19 (1.98) | 3.20; 5.17 | 3.98 (2.74; 5.57) | 35 | 4.99 (1.66) | 4.42; 5.56 | 5.19 (4.31; 5.77) | 0.117f | ||
| Weight, SDS | 37 | −3.14 (0.89) | −3.43; −2.84 | −3.09 (−3.52; −2.68) | 50 | −3.07 (1.02) | −3.36; −2.78 | −3.04 (−3.52; −2.57) | 0.758e | ||
| BMI, SDS | 33 | −1.11 (1.30) | −1.57; −0.65 | −1.27 (−1.90; −0.11) | 44 | −0.67 (1.28) | −1.06; −0.28 | −0.73 (−1.26; 0.19) | 0.138e | ||
| Mother’s height, cm | 36 | 158.4 (7.9) | 155.7; 161.1 | 158.5 (153.3; 165.0) | 46 | 158.6 (6.8) | 156.5; 160.6 | 158.0 (155.0; 162.0) | – | ||
| Father’s height, cm | 36 | 174.8 (7.6) | 172.3; 177.4 | 174.5 (170.0; 180.0) | 46 | 171.4 (8.1) | 169.0; 173.8 | 172.0 (167.0; 176.0) | – | ||
| IGF1, ng/mL | 35 | 110.32 (77.11) | 83.83; 136.80 | 91.00 (61.00; 139.00) | 42 | 86.97 (69.95) | 65.17; 108.76 | 68.25 (31.30; 110.00) | 0.069f | ||
| Peak stimulated GH level, ng/mL | 27 | 22.51 (19.08) | 14.96; 30.05 | 16.01 (11.50; 24.40) | 35 | 24.76 (27.15) | 15.43; 34.08 | 13.60 (10.90; 26.10) | 0.865f | ||
| Primary diagnosis: SPIGFD† | 38 | 35 (92.1) | 79.2; 97.3 | 50 | 43 (86.0) | 73.8; 93.0 | – | ||||
| History of hypoglycaemia | 38 | 0 | 0; 9.2 | 50 | 2 (4.0) | 1.1; 13.5 | 0.504d | ||||
†Including LS, as reported by the investigator. aNPP-non-LS poor-responder vs NPP-non-LS responder; bnumber of patients with available data. cChi-square test; dFisher’s test; eANOVA; fWilcoxon test.
BMI, body mass index; GH, growth hormone; IGF1, insulin-like growth factor-1; LS, Laron syndrome; SDS, standard deviation score; SPIGFD, severe primary IGF1 deficiency.